Clinical Trial Update: Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial of KITE-585 in relapsed/refractory multiple myeloma was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• KITE-585

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1 | Status: TERMINATED | Results posted: 2020-05-26